Research programme: hypocretin receptor 2 agonists - Neurocrine
Latest Information Update: 24 Feb 2011
Price :
$50 *
At a glance
- Originator Neurocrine Biosciences
- Class
- Mechanism of Action Hypocretin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Narcolepsy
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Narcolepsy in USA (unspecified route)
- 07 Jul 2006 No development reported - Preclinical for Narcolepsy in USA (unspecified route)
- 09 Jan 2002 Preclinical development for Narcolepsy in USA (Unknown route)